Cargando…
An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review
Biological therapies have revolutionized the treatment of disease across a number of therapeutic areas including retinal diseases. However, on occasion, such treatments may be relatively more expensive compared to small molecule therapies. This can restrict patient access and treatment length leadin...
Autores principales: | Hariprasad, Seenu M., Gale, Richard P., Weng, Christina Y., Ebbers, Hans C., Rezk, Mourad F., Tadayoni, Ramin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9114261/ https://www.ncbi.nlm.nih.gov/pubmed/35278204 http://dx.doi.org/10.1007/s40123-022-00488-w |
Ejemplares similares
-
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019) -
Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect
por: Rezk, Mourad F., et al.
Publicado: (2017) -
Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
por: Rezk, Mourad F., et al.
Publicado: (2020) -
Correction to: Unlocking the Value of Anti-TNF Biosimilars: Reducing Disease Burden and Improving Outcomes in Chronic Immune-Mediated Inflammatory Diseases: A Narrative Review
por: Rezk, Mourad F., et al.
Publicado: (2020) -
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020)